Intravitreal Bevacizumab for the Treatment of Chronic or Recurrent Central Serous Chorioretinopathy

摘要: Background: We report the use of intravitreal bevacizumab as an option for treatment chronic or recurrent central serous chorioretinopathy (CSC). Methods: Eight eyes with CSC received (1.25 mg/0.05 cc) and underwent best corrected visual acuity (VA), optical coherent tomography (OCT), fluorescein angiography (FA) indocyanine green (ICG) before, one, three six months after treatment. Results: All patients showed improvement in acuity, angiographic leakage, choroidal hyperpermeability reduced resolved neurosensory detachment following Two require a second dose bevacizumab. Conclusions: Intravitreal injection was associated without adverse events CSC. Although these results are promising, further investigations would be helpful to understand this therapy